Caribou Biosciences, Inc.
CRBU
$1.96
$0.084.26%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -72.45% | -70.31% | -71.01% | -66.85% | 132.34% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -72.45% | -70.31% | -71.01% | -66.85% | 132.34% |
| Cost of Revenue | -1.18% | -27.92% | -43.52% | -39.26% | -35.19% |
| Gross Profit | -76.56% | 1.97% | 31.31% | 25.98% | 63.72% |
| SG&A Expenses | -19.74% | -14.81% | 10.65% | 12.12% | 21.78% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -8.71% | 2.43% | 13.93% | 19.72% | 29.07% |
| Operating Income | -6.20% | -20.99% | -39.17% | -47.15% | -16.91% |
| Income Before Tax | -33.29% | -28.51% | -46.37% | -56.56% | -10.90% |
| Income Tax Expenses | -104.66% | -104.66% | -104.66% | 175.71% | 175.71% |
| Earnings from Continuing Operations | -33.07% | -28.29% | -46.08% | -56.65% | -11.01% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -33.07% | -28.29% | -46.08% | -56.65% | -11.01% |
| EBIT | -6.20% | -20.99% | -39.17% | -47.15% | -16.91% |
| EBITDA | -5.79% | -21.01% | -40.04% | -48.44% | -15.77% |
| EPS Basic | -28.60% | -11.68% | -14.03% | -10.12% | 23.66% |
| Normalized Basic EPS | -15.42% | -8.03% | -10.40% | -6.80% | 23.72% |
| EPS Diluted | -28.60% | -11.68% | -14.03% | -10.12% | 23.66% |
| Normalized Diluted EPS | -15.42% | -8.03% | -10.40% | -6.80% | 23.72% |
| Average Basic Shares Outstanding | 4.40% | 12.91% | 22.54% | 34.09% | 43.91% |
| Average Diluted Shares Outstanding | 4.40% | 12.91% | 22.54% | 34.09% | 43.91% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |